InsiderTrades.com logo
Daniel B. Soland net worth and biography
  • Phone
  • Email
  • Website

Daniel Soland Biography and Net Worth

Director of DBV Technologies

Daniel Soland has served as a member of DBV’s Board of Directors since 2015. Mr. Soland most recently served as Senior Vice President and Chief Operating Officer of Viropharma, and currently serves on the Board of Directors of Tarsa Therapeutics. Mr. Soland previously served as President of Chiron Vaccines, and helped engineer a turnaround that contributed to the acquisition of Chiron by Novartis. Prior to that, he was President and Chief Executive Officer of Epigenesis Pharmaceuticals and also served as CEO, uniQure. At GlaxoSmithKline Biologicals, Mr. Soland served as Vice President and Director, Worldwide Marketing Operations. Earlier in his career, Mr. Soland held positions of increasing responsibility in sales and product management at Pasteur-Merieux’s Connaught Laboratories. He holds a B.S. in Pharmacy from the University of Iowa.

What is Daniel B. Soland's net worth?

The estimated net worth of Daniel B. Soland is at least $26.10 thousand as of August 1st, 2023. Soland owns 2,000 shares of DBV Technologies stock worth more than $26,100 as of December 5th. This net worth estimate does not reflect any other investments that Soland may own. Learn More about Daniel B. Soland's net worth.

How do I contact Daniel B. Soland?

The corporate mailing address for Soland and other DBV Technologies executives is 177-181 AVENUE PIERRE BROSSOLETTE, MONTROUGE I0, 92120. DBV Technologies can also be reached via phone at (315) 542-7878 and via email at [email protected]. Learn More on Daniel B. Soland's contact information.

Has Daniel B. Soland been buying or selling shares of DBV Technologies?

Daniel B. Soland has not been actively trading shares of DBV Technologies in the last ninety days. Most recently, on Tuesday, August 1st, Daniel B. Soland bought 1,500 shares of DBV Technologies stock. The stock was acquired at an average cost of $16.20 per share, with a total value of $24,300.00. Following the completion of the transaction, the director now directly owns 2,000 shares of the company's stock, valued at $32,400. Learn More on Daniel B. Soland's trading history.

Who are DBV Technologies' active insiders?

DBV Technologies' insider roster includes Pharis Mohideen (Chief Medical Officer), Timothy Morris (Director), Adora Ndu (Director), and Daniel Soland (Director). Learn More on DBV Technologies' active insiders.

Are insiders buying or selling shares of DBV Technologies?

In the last twelve months, insiders at the sold shares 3 times. They sold a total of 1,461 shares worth more than $2,270.56. The most recent insider tranaction occured on July, 29th when insider Pharis Mohideen sold 464 shares worth more than $1,030.08. Insiders at DBV Technologies own 1.4% of the company. Learn More about insider trades at DBV Technologies.

Information on this page was last updated on 7/29/2025.

Daniel B. Soland Insider Trading History at DBV Technologies

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/1/2023Buy1,500$16.20$24,300.002,000View SEC Filing Icon  
See Full Table

Daniel B. Soland Buying and Selling Activity at DBV Technologies

This chart shows Daniel B Soland's buying and selling at DBV Technologies by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

DBV Technologies Company Overview

DBV Technologies logo
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs includes vaccine for the respiratory syncytial virus, potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes. In addition, it develops Viaskin technology platform, a platform to potentially treat food allergy. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.
Read More

Today's Range

Now: $13.05
Low: $12.96
High: $13.42

50 Day Range

MA: $13.96
Low: $9.14
High: $17.00

2 Week Range

Now: $13.05
Low: $2.74
High: $18.00

Volume

978,247 shs

Average Volume

248,892 shs

Market Capitalization

$469.41 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A